New Perspectives in the Therapy of Castration Resistant Prostate Cancer

Author(s): Pasquale Rescigno, Carlo Buonerba, Joaquim Bellmunt, Guru Sonpavde, Sabino De Placido, Giuseppe Di Lorenzo.

Journal Name: Current Drug Targets

Volume 13 , Issue 13 , 2012

Become EABM
Become Reviewer

Abstract:

Prostate Cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in men in the Western World. Docetaxel-based chemotherapy has been the mainstay of treatment until a few years ago for metastatic castration resistant prostatic cancer (mCRPC). Recently, a broad range of therapeutic options has become available for mCRPC in a variety of settings, including chemotherapeutic agents (cabazitaxel), androgen synthesis inhibitors (abiraterone acetate), androgen receptor (AR) inhibitors (enzalutamide) and immunotherapy (sipuleucel-T). Multiple novel targeted agents are at an advanced stage of experimentation, including androgen synthesis inhibitors (TAK700), AR inhibitors (ARN509), radiopharmaceuticals (radium-223) and immunotherapeutic agents (poxvirus-based vaccine, ipilimumab). This review describes in detail the latest results obtained with a the most promising agents in prostate cancer, with a focus on CRPC biology and mechanism of resistance to anti-neoplastic treatment.

Keywords: Chemotherapy, hormonal therapy, immunotherapy and targeted therapy, metastatic castration-resistant prostate cancer, Chemotherapy, hormonal therapy, immunotherapy and targeted therapy, metastatic castration-resistant prostate cancer, chemotherapeutic agents (cabazitaxel), "androgen synthesis inhibitors (abiraterone acetate)", immunotherapy (sipuleucel-T), androgen receptor (AR) inhibitors (enzalutamide), androgen synthesis inhibitors(TAK700), radiopharmaceuticals (radium-223)

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 13
Year: 2012
Page: [1676 - 1686]
Pages: 11
DOI: 10.2174/138945012803529956
Price: $65

Article Metrics

PDF: 31

Special-new-year-discount